To evaluate associations by EGFR mutation status for lung adenocarcinoma risk among never-smoking Asian women, we conducted a meta-analysis of 11 loci previously identified in genome-wide association studies (GWAS). Genotyping in an additional 10,780 never-smoking cases and 10,938 never-smoking controls from Asia confirmed associations with eight known single nucleotide polymorphisms (SNPs). Two new signals were observed at genome-wide significance (P < 5 Â 10 À8 ), namely, rs7216064 (17q24.3, BPTF), for overall lung adenocarcinoma risk, and rs3817963 (6p21.3, BTNL2) which is specific to cases with EGFR mutations. In further sub-analyses by EGFR status, rs9387478 (ROS1/DCBLD1) and rs2179920 (HLA-DPB1) showed stronger estimated associations in EGFR-positive compared to EGFR-negative cases. Comparison of the overall associations with published results in Western populations revealed that the majority of these findings were distinct, underscoring the importance 457 Human Molecular Genetics, 2017, Vol. 26, No. 2 | of distinct contributing factors for smoking and non-smoking lung cancer. Our results extend the catalogue of regions associated with lung adenocarcinoma in non-smoking Asian women and highlight the importance of how the germline could inform risk for specific tumour mutation patterns, which could have important translational implications.
Abstract
To evaluate associations by EGFR mutation status for lung adenocarcinoma risk among never-smoking Asian women, we conducted a meta-analysis of 11 loci previously identified in genome-wide association studies (GWAS). Genotyping in an additional 10,780 never-smoking cases and 10,938 never-smoking controls from Asia confirmed associations with eight known single nucleotide polymorphisms (SNPs). Two new signals were observed at genome-wide significance (P < 5 Â 10 À8 ), namely, rs7216064 (17q24.3, BPTF), for overall lung adenocarcinoma risk, and rs3817963 (6p21.3, BTNL2) which is specific to cases with EGFR mutations. In further sub-analyses by EGFR status, rs9387478 (ROS1/DCBLD1) and rs2179920 (HLA-DPB1) showed stronger estimated associations in EGFR-positive compared to EGFR-negative cases. Comparison of the overall associations with published results in Western populations revealed that the majority of these findings were distinct, underscoring the importance of distinct contributing factors for smoking and non-smoking lung cancer. Our results extend the catalogue of regions associated with lung adenocarcinoma in non-smoking Asian women and highlight the importance of how the germline could inform risk for specific tumour mutation patterns, which could have important translational implications.
Introduction
Lung cancer is a prominent global health burden that accounts for approximately 1.5 million annual deaths worldwide (1) . It is also the leading cause of cancer mortality among women in China, accounting for 21.3% of all cancer deaths in 2010, even though the majority of Asian women do not smoke (2) . Although tobacco smoking is a major risk factor for lung cancer, approximately 25% of all lung cancer cases occur in neversmokers (3) . We previously conducted a multi-stage genomewide association study (GWAS) of lung cancer among neversmoking women in the Female Lung Cancer Consortium in Asia (FLCCA) and identified eight lung cancer susceptibility loci on chromosomes 3q28, 5p15.33, 6p21.1, 6p21.32, 6q22.2, 9p21.3, 10q25.2 and 12q13.13 (4, 5) . Most of these loci were distinct from those identified in smokers of European-ancestry; suggesting that the genetic susceptibility and the aetiology of lung cancer could differ between groups of distinct ancestral origin but more importantly by smoking status (6) (7) (8) (9) (10) (11) .
Epidermal growth factor receptor (EGFR) is a transmembrane protein important for the regulation of cellular proliferation and apoptosis (12) . Mutations in the EGFR gene are a defining hallmark of lung adenocarcinoma, which commonly occur in exons 18-21 (tyrosine kinase encoding region). EGFR mutation rates in lung cancer tumours are generally higher in Asian compared to Western populations, non-smokers compared to smokers, women compared to men, and the adenocarcinoma subtype compared to other subtypes (13, 14) . Lung adenocarcinoma patients harbouring different EGFR mutations have differential responses to tyrosine kinase inhibitor treatment, which is increasingly used as a targeted therapy (15, 16) .
We conducted a meta-analysis with further follow-up genotyping in never-smoking Asian women (11,725 lung adenocarcinoma cases and 14,490 controls) to investigate the possible association between EGFR mutation status and common genetic susceptibility alleles as well as the identification of new risk loci; 11 SNPs were selected for the analysis. Eight SNPs, corresponding to known susceptibility alleles were significantly associated with lung adenocarcinoma at a genome-wide significance level (P < 5 Â 10
À8
) among never-smoking Asian women (rs2736100 (TERT), rs4488809 (TP63), rs7086803 (VTI1A), rs11610143 (12q13.13), rs72658409 (9p21.3), rs7741164 (FOXP4), rs9387478 (ROS1/DCBLD1), and rs2395185 (HLA class II)); however, these associations have not been previously evaluated by EGFR mutation status (4, 5) . The additional SNPs (N ¼ 3) were identified from two previous Japanese GWAS of lung adenocarcinoma (rs3817963 (BTNL2), rs7216064 (BPTF)) or in tumour subgroups (i.e., carrying EGFR mutations) (rs2179920 (HLA-DPB1)) (17, 7) . However, associations with these SNPs have yet to be found in never-smoking women. Because the EGFR mutation status affects targeted therapy, and nearly 50% of lung adenocarcinoma in the Asian population have EGFR mutations (13, 17) , we evaluated the associations between the 11 SNPs and lung adenocarcinoma risk among neversmoking Asian women, differentiated by EGFR mutation status. Further, we compared the findings with results in Western populations.
Results
We conducted a fixed effects meta-analysis of case-control studies that included a total of 11,725 never-smoking female lung adenocarcinoma cases and 14,490 never-smoking controls from the FLCCA, the Nanjing GWAS study and the Japanese Lung Cancer Collaborative Study (JLCCS) (Supplementary Material, Tables S1-S3 ). There were 3,576 lung adenocarcinoma cases with EGFR data in the FLCCA and JLCCS study.
Case-control comparisons
In the meta-analysis, we observed that the SNP marker, rs7216064 (BPTF, odds ratio (OR) ¼ 0. Table S5 ). This finding is in contrast to the comparison between lung adenocarcinoma cases with tumours without EGFR mutations (EGFR-negative), for which the association was weaker (BTNL2, OR ¼ 1.18, P ¼ 1.52 Â 10 À3 ), thus suggesting the contribution of the germline variants in EGFR mutation-positive lung adenocarcinoma. In the EGFR-specific analyses, there was a suggestion that the estimated OR may be higher in the subset with EGFR mutations in the tyrosine kinase region for six of 11 SNPs; the remaining five did not indicate a difference by EGFR status.
Case-case comparisons
In the meta-analysis of case-case comparisons, we evaluated the associations between each of the 11 SNPs and the occurrence of EGFR mutation in lung adenocarcinoma tissues. We found a statistically significant association between two SNPs, rs2179920 (HLA-DPB1, OR ¼ We used all previously reported GWAS and Taqman data from Female Lung Cancer Consortium in Asia (FLCCA), one independent GWAS from Nanjing (4,5) and
Taqman data from the Japanese Lung Cancer Collaborative Study (JLCCS). We excluded FLCCA GWAS and Taqman data from overlapping subjects with the JLCCS. (Supplementary Material, Table S8 ). We excluded seven study centres which did not provide EGFR information and the results were similar (data not shown).
Association of SNPs identified from studies of nonsmoking Asian women in Western never-smokers and smokers
Of the 10 SNPs observed to be associated with lung adenocarcinoma risk never-smoking Asian women, three SNP markers, in TERT, TP63 and 9p21.3 were significantly associated with lung adenocarcinoma risk in a small pooled study of Western never smokers (P < 0.05) (Supplementary Material, 
Association of SNPs identified from studies in Western populations among non-smoking Asian women
We analysed 15 SNPs identified from an extensive set of lung cancer GWAS among Western populations that showed significant associations for overall lung cancer or specific histologies (i.e., adenocarcinoma or squamous cell carcinoma) conducted to date (6, 7, (18) (19) (20) (21) (22) (23) (24) in our pooled GWAS dataset of neversmoking Asian women population (Supplementary Material, Table S11 ) and identified only two overlapping loci, marked by SNPs rs2736100 (TERT) and rs4488809 (TP63), which achieved genome-wide significance in our dataset of up to 5,512 cases and 6,277 controls.
Discussion
In our meta-analysis, two new SNPs (rs7216064, BPTF and rs3817963, BTNL2) achieved genome wide significance for lung adenocarcinoma risk in never-smoking Asian women. Additionally, we found that two loci at 6q22.2 (rs9387478, ROS1/ DCBLD1) and 6p21.32 (rs2179920, HLA-DPB1) were more strongly associated with risk in EGFR-positive cases compared to EGFRnegative lung adenocarcinoma. We also confirmed eight previous GWAS signals (rs11610143 (12q13.13), rs2736100 (TERT), rs4488809 (TP63), rs2395185 (HLA class II), rs7086803 (VTI1A), rs72658409 (9p21.3), rs7741164 (FOXP4), and rs9387478 (ROS1/ DCBLD1)) and risk of lung adenocarcinoma among neversmoking Asian women. Overall, we observed genome-wide significant associations for 10 of the 11 SNPs tested; the one remaining SNP showed a borderline association, which might have been due to the reduced sample size for this marker. One of the new loci at 17q24.3 (rs7216064, BPTF) maps to a plausible candidate gene, the bromodomain PHD finger transcription factor (BPTF), which is the largest subunit of a nucleosome-remodeling factor that regulates transcription and the development of eukaryotic cells. A recent study showed BPTF to be highly expressed in non-small cell lung cancer (NSCLC) cell lines and tumour tissues compared to normal tissues and that its overexpression predicted a poor prognosis in lung adenocarcinoma patients (25) . The second new locus associated with EGFR mutation status maps to the markers in the vicinity of the butyrophilin-like 2 (BTNL2) gene in MHC class II in the HLA region of chromosome 6, which is a negative regulator of T-cell proliferation and has already been shown to be associated with several immune-associated diseases (26) . The discovery of a new HLA signal highlights the importance of immune regulation in adenocarcinogenesis.
The SNP marker, rs9387478 resides in the vicinity of several plausible candidate genes, ROS proto-oncogene receptor tyrosine kinase (ROS1) and discoidin, CUB and LCCL domain containing 1 (DCBLD1) genes; its association with lung adenocarcinoma in never-smoking Asian women suggests regulation of one or more of these genes could be critical in primary lung adenocarcinogenesis (4) . Notably, this is the first study to report differential associations by EGFR mutation status for a genetic variant in the ROS1/DCBLD1 gene. Similar to EGFR, the ROS1 gene codes for a protein with tyrosine kinase activity. ROS1 rearrangements are defined as a unique genetic subtype of lung adenocarcinoma that are more commonly found in never-smokers and younger individuals (27) . Further, in vitro evidence in NSCLC tumour cells indicates that the EGFR pathway is activated as a mechanism of resistance to ROS1 inhibition (28), suggesting a potential interaction between the genes.
A genetic variant in HLA-DPB1 was also significantly associated with EGFR-positive lung adenocarcinoma. Class II major histocompatibility complex, DP beta 1 (HLA-DPB1) encodes a human MHC Class II lymphocyte antigen b chain and plays an important role in regulating the immune system. Interestingly, a previous study identified HLA-DPB1 as part of a 39-gene signature that was differentially expressed among the lung adenocarcinoma patients and showed lower expression of HLA-DPB1 to be associated with poor survival (29) . Our study demonstrates the association of this region in never-smoking Asian women, consistent with a concurrent report (30) . Our findings suggest a genetic predisposition to the acquisition of EGFR mutations among lung adenocarcinoma cases but not among lung cancer cases compared to controls, which could inform our understanding of how specific germline variants influence the acquisition of specific mutational patterns in lung adenocarcinoma. Given the high prevalence of EGFR mutations in lung adenocarcinomas of Asian populations, and that the efficacy of targeted therapies is influenced by EGFR status, findings from this study may help guide clinical decision making.
Except for the TERT and TP63 gene regions, which were drawn from the ten genome-wide significant signals in our population, there was no evidence that other signals were identified in Western studies for all or specific lung cancer histologies to date (6, 7, (18) (19) (20) (21) (22) (23) (24) ; notably we did not see a signal at the 15q25 locus, which is associated with smoking and nicotine dependence, and would not necessarily be expected to show the association in our non-smoking population 4 . Overall, this suggests striking differences between Asian and Western populations that could be partially due to differences in the underlying genetic architecture of lung adenocarcinoma by ancestral history, but more likely is due to smoking status, or other distinct environmental exposures such as stove ventilation (31), household coal use (32), diet (33) and cooking fumes (34). Shiraishi et al. (35) compared a number of these associations between men and women, as well as between smokers and non-smokers in the Japanese population, and found no differences in the association for some SNPs and equivocal results for others. Further studies are needed to clarify the differences and provide new opportunities to understand the interaction of environmental risk factors with underlying genetic susceptibility to a common cancer, such as lung adenocarcinoma, which is a major global health problem.
In summary, we identified two new regions, namely SNPs, rs7216064 (BPTF) and rs3817963 (BTNL2), that were associated with risk for lung adenocarcinoma in never-smoking Asian women. Furthermore, we confirmed the strength of eight known loci. Together, we now have observed associations for ten loci in relation to lung cancer risk in non-smoking Asian women. In our analyses, we also observed two loci, namely, rs9387478 (ROS1/DCBLD1) and rs2179920 (HLA-DPB1), that were associated with lung adenocarcinoma cases with EGFR-positive mutations. The identification of such genetic variants establishes a foundation for investigating how and in what way the germline variants can inform our understanding of somatic patterns, particularly here, a mutational spectrum that is amenable to new targeted therapies. In turn, this could have important public health implications with respect to risk stratification, screening and treatment for lung cancer among never-smoking women in Asia. Future studies are warranted to expand on these findings and evaluate the contribution of geneenvironment interactions on the acquisition of EGFR mutations (36).
Materials and Methods

Study population
Female lung cancer consortium in Asia (FLCCA) and Nanjing GWAS We utilized all GWAS and Taqman data from the FLCCA and one other independent GWAS from Nanjing for this study. FLCCA consists of epidemiological studies of lung cancer, which are restricted to never-smoking female lung cancer cases and never-smoking female controls (Supplementary Material, Table  S1 ). FLCCA included studies from Mainland China, Hong Kong, Taiwan, Singapore, Japan, and South Korea, and its efforts have been previously described (4, 5) . Details on the Nanjing GWAS were described in a previous publication (37) .
In addition to using all previously reported data (4,5) in this pooling effort, 11 study centres in the FLCCA contributed EGFR mutation status data (Supplementary Material, Table S2 ). These 11 study centres include the Chinese Academy of Medical Sciences Cancer Hospital Study (CAMSCH), the Guangdong Study (GDS), the Genetic Epidemiological Study of Lung Adenocarcinoma (GELAC), the Hong Kong Study (HKS), the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), the Japan National Cancer Center (NCC), the South Korea Multi-Center Lung Cancer Study (SKLCS-Korea University, Kyungpook University, Seoul National University Department of Preventive Medicine (SNUPM)), the Chonnam National University Lung Cancer Study (CNUCLS), and the Tianjin Lung Cancer Study (TLCS), which have all been previously described (4, 10, (38) (39) (40) (41) (42) (43) (44) . All studies were case-control by design. All lung cancer cases were histologically confirmed. Each study was approved by their local institutional review board and all study participants provided informed consent prior to participation.
Japanese lung cancer collaborative study (JLCCS) Details of the JLCCS study population have been described elsewhere (30) and their characteristics are shown in the Supplementary Material, Table S3 . Briefly, JLCCS consists of lung adenocarcinoma cases and cancer-free, healthy controls from the BioBank Japan project (45) , National Cancer Center Hospital (NCCH), National Cancer Center Hospital East (NCCHE), Kanagawa Cancer Center, Akita University Hospital and Gunma University Hospital. We excluded FLCCA GWAS and Taqman data from Japanese study centers consisting of overlapping subjects with the JLCCS. This study was approved by the ethics committees of each participating institution and all the participants provided written informed consent.
Genetic data
FLCCA and Nanjing GWAS Genotyping and imputation for the FLCCA and Nanjing GWAS studies were previously described (4, 5, 37, 46) . Briefly, samples were genotyped using the Illumina 660W SNP microarray, Illumina 370K SNP microarray, Illumina 610Q SNP microarray, AffymetrixGenome-WideSNPArray6.0 and TaqMan custom genotyping assay (only for FLCCA samples) (Applied Biosystems, CA, USA). Genotype imputation was conducted by using IMPUTE2 software version 2.2.2 and the 1,000 Genomes Project Phase 1 version 3 data as the reference panel (5) .
JLCCS
The 11 SNPs were genotyped using the TaqMan method or multiplex PCR-based Invader assay (Third Wave Technologies), according to the manufacturer's protocol as previously described (30) . Genotyping data on five of the 11 SNPs (HLA-DPB1, TERT, BTNL2, TP63, BPTF) were presented in a GWAS of EGFR-positive lung adenocarcinoma in a larger study population in Japan (30) . Data on the other six SNPs (12q13.13, HLA class II, VTI1A, 9p21.3, FOXP4, ROS1/DCBLD1) are presented for the first time in this study.
EGFR tumour mutation
Both FLCCA and JLCCS provided EGFR information. Details on DNA extraction methods used by each study center have been previously described (4, 5, 30) . Genomic DNA was extracted from fresh, frozen or formalin-fixed, paraffin-embedded (FFPE) samples, following the respective manufacturer's protocols. Each participating study independently genotyped the tumour tissues from lung cancer cases for EGFR mutations on exons 19 and 21 using polymerase chain reaction (PCR) based sequencing (16, 47, 48) , Peptide Nucleic Acid (PNC) Clamping (49), a cycleave PCR technique (50), high-resolution melting (HRM) analysis (51), invader assay (52) and SCORPION-ARMS (53) . Cases with EGFR mutation on either exon 19 or 21 were defined as being EGFRpositive. Cases for whom genotyping for EGFR events yielded null findings were deemed as not having an EGFR mutation (EGFR-negative).
Statistical analyses
We restricted our analyses to 11 SNPs that achieved genomewide significance (i.e., P 5 Â 10 À8 ) in previous GWAS studies of various populations and subgroups in Asia: rs11610143 (12q13.13), rs2179920 (HLA-DPB1), rs2395185 (HLA class II), rs2736100 (TERT), rs3817963 (BTNL2), rs4488809 (TP63), rs7086803 (VTI1A), rs7216064 (BPTF), rs72658409 (9p21.3), rs7741164 (FOXP4) and rs9387478 (ROS1/DCBLD1). Each SNP was coded as the number of minor alleles (in controls) a subject carried (additive model). Subjects from FLCCA were consisted of three major racial/ethnic groups (self-reported) which included Chinese, Korean, and Japanese (Supplementary Material, Table S1 ). All analyses were restricted to lung adenocarcinoma patients only.
To assess associations between each SNP and EGFR mutations in the tumours (dichotomous, presence or absence of EGFR mutation), logistic regression models adjusted for age (10-year categories: <40, 40-49, 50-59, 60-69 and !70), racial/ethnic groups (Chinese, Korean and Japanese) and significant eigenvectors (EV1, EV2, EV4, EV6, EV7 and EV8 for case-control analysis; EV1, EV2, EV6 and EV7 for EGFR-positive (or EGFR-negative) case-control analysis) were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Three different comparisons were carried out -1) case-control (FLCCA, Nanjing and JLCCS), 2) EGFR-positive (or EGFR-negative) case-control (included only cases with EGFR mutation from FLCCA and JLCCS), and 3) all cases only (compared cases with and without EGFR mutation from FLCCA and JLCCS). A fixed effect meta-analysis was used to estimate the overall effect in each of the analyses and the Cochran's Q statistic was used to test for heterogeneity across studies.
Sensitivity analyses for the 11 SNPs in the subgroup of subjects who did not contribute any EGFR mutation data yielded very similar results for overall case-control associations and had similar age distribution as those who contributed EGFR mutation data (data not shown). We also stratified the case-case analysis by the major racial/ethnic groups (Chinese and Japanese).
All statistical analyses were conducted using R, version 3.2.2 (54). Multiple comparisons were adjusted for by calculating the false discovery rate (FDR) using the Benjamini-Hochberg method (55) . All statistical tests were conducted as two-sided, and a P-value of < 5 Â 10 À8 was considered as genome-wide significant for the case-control analyses and an FDR of 0.15 was considered significant for the case-case analyses.
Comparison of SNP associations between Asian and Western populations
We examined the associations of our 10 statistically significant SNPs and lung adenocarcinoma risk in a separate population of never-smokers (219 lung adenocarcinoma cases and 1,379 controls) and smokers (1,612 lung adenocarcinoma cases and 4,336 controls) of European ancestry in the NCI GWAS consisting of The Environment and Genetics in Lung Cancer Etiology (EAGLE) study; Prostate, Lung, Colon, Ovary (PLCO) Screening Trial; the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Trial, and the Cancer Prevention Study-II (CPS-II) Nutrition Cohort (6) . Further, to determine if there are shared regions in GWAS reports for lung adenocarcinoma between neversmoking women in Asia and predominately smoking studies in Western populations, we analysed known signals from Western populations that showed significant associations for all or specific lung cancer histologies to date (6, 7, (18) (19) (20) (21) (22) (23) (24) for those SNPs that we had genotyping data, in our never-smoking Asian women population.
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